Studybox Research Dual Submission Studies
COVID-19 Rapid Antigen Test
One integrated study supporting both 510(k) clearance and CLIA waiver.
Studybox
Dual Submission Studies
SARS-CoV-2 antigen tests entered the market under Emergency Use Authorization, and sponsors are now moving them to traditional marketing authorization as EUAs are transitioned. The clinical evidence expectations carried over from the EUA templates: prospective enrollment of symptomatic subjects early in illness, a paired high-sensitivity molecular comparator, and reporting of comparator cycle threshold values so that reviewers can see whether the antigen test's sensitivity depends on the viral load distribution of the enrolled population.
Enrollment is harder than it was. Prevalence is lower and less predictable, most positives come from people with prior infection or vaccination who carry lower viral loads, and widespread home testing means many symptomatic people never present to a clinic. Studies now typically run across multiple waves and many sites, and home-use versions add lay user studies in which untrained consumers collect, run and interpret the test without assistance.
- Analyte
- SARS-CoV-2 nucleocapsid antigen
- Therapeutic area
- Infectious Disease
- Specimens
- Anterior Nares (Nasal) Swab, Nasopharyngeal (NP) Swab
- Intended-use settings
- urgent care, physician office, pharmacy, home use, hospital POC, emergency department
- Operators
- Non-laboratory clinic staff in waived settings; lay users self-testing, or testing a child, for over-the-counter claims.
- Comparator
- Typically a high-sensitivity FDA-authorized or cleared SARS-CoV-2 RT-PCR assay on a paired swab, with the comparator's cycle threshold values recorded for each positive.
Dual Submission specifics
What Changes for This Assay on This Pathway.
- A combined protocol enrolls symptomatic subjects at waived sites with untrained operators and uses the same paired molecular comparator for both the 510(k) comparison and the waiver demonstration.
- Home-use claims are typically pursued in the same program with a lay user arm, so the integrated study may have three operator populations: untrained site staff, lay users and, for a moderate-complexity reference, laboratory staff.
- The analytical package (limit of detection against characterized viral stock, inclusivity across variants, cross-reactivity against other respiratory pathogens) is reviewed with the clinical data, and variant inclusivity is a recurring update obligation.
Endpoints the study must support
- Positive and negative percent agreement against the molecular comparator in symptomatic subjects within the claimed window after symptom onset, with 95% confidence intervals
- Performance by days since symptom onset and by comparator cycle threshold distribution, to show that positives were not skewed toward high viral loads
- For serial-testing or asymptomatic claims, agreement across a defined repeat-testing schedule
- For home-use claims, lay user agreement with the comparator and labeling comprehension
Enrollment realities
Sample size is driven by the number of molecular-positive symptomatic subjects within the claimed window; with lower and unpredictable prevalence, enrollment typically runs across several months and many sites, and sponsors should plan for a wave-dependent accrual rate rather than a steady one. Not strictly seasonal; circulation rises in winter and in periodic variant-driven waves, so enrollment is planned around surveillance data rather than a calendar season.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run dual submission studies →
Same assay, other pathways
Relevant FDA guidance
- Design Considerations for Devices Intended for Home Use
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
COVID-19 Rapid Antigen Test Study Questions.
01 Who operates the covid-19 rapid antigen test in a dual submission study?
Non-laboratory clinic staff in waived settings; lay users self-testing, or testing a child, for over-the-counter claims.
02 What is the comparator for a covid-19 rapid antigen test study?
Typically a high-sensitivity FDA-authorized or cleared SARS-CoV-2 RT-PCR assay on a paired swab, with the comparator's cycle threshold values recorded for each positive.
03 What drives enrollment for a covid-19 rapid antigen test study?
Sample size is driven by the number of molecular-positive symptomatic subjects within the claimed window; with lower and unpredictable prevalence, enrollment typically runs across several months and many sites, and sponsors should plan for a wave-dependent accrual rate rather than a steady one. Not strictly seasonal; circulation rises in winter and in periodic variant-driven waves, so enrollment is planned around surveillance data rather than a calendar season.
Let's talk IVD research
Planning a covid-19 rapid antigen test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the dual submission pathway.